CP-751,871 Phase 3 trial for advanced non-small cell lung cancer terminated without reported efficacy or safety findings

Advanced non-small cell lung cancer (NSCLC) represents a significant global health challenge, characterized by aggressive progression and poor prognosis despite therapeutic advancements. Conventional platinum-based chemotherapy regimens, while foundational, often yield limited durable responses and are associated with considerable toxicities, highlighting an urgent need for more effective and targeted treatments. The insulin-like growth factor 1 receptor (IGF-1R) signaling pathway is a critical mediator of cell growth, proliferation, survival, and metastasis in various cancers, including NSCLC. Overexpression or dysregulation of IGF-1R can promote tumor cell survival, resistance to apoptosis, and angiogenesis, making it an attractive therapeutic target. CP-751,871, a fully human monoclonal antibody designed to specifically inhibit IGF-1R, was developed with the rationale that blocking this pathway could sensitize cancer cells to chemotherapy and improve patient outcomes in NSCLC.

This Phase 3, randomized, open-label, multi-center trial (NCT00596830) was designed to investigate CP-751,871 in combination with standard first-line chemotherapy, specifically paclitaxel and carboplatin, for patients diagnosed with advanced non-small cell lung cancer. The study aimed to compare the safety, tolerability, pharmacokinetics, and efficacy of the combination therapy against paclitaxel and carboplatin alone. Participants were randomized to receive either the experimental combination or the control regimen. The trial was planned to enroll a larger cohort to detect statistically significant differences in clinical endpoints, but it was prematurely terminated after enrolling only 6 participants, preventing the full execution of its design and objectives.